TSG6 Plays a Role in Improving Orbital Inflammatory Infiltration and Extracellular Matrix Accumulation in TAO Model Mice
Xiuhui He,Siya Chen,Xiaohui Wang,Min Kong,Fangzheng Shi,Xiaoxuan Qi,Yuxin Xu
DOI: https://doi.org/10.2147/jir.s409286
IF: 4.5
2023-05-04
Journal of Inflammation Research
Abstract:Xiuhui He, Siya Chen, Xiaohui Wang, Min Kong, Fangzheng Shi, Xiaoxuan Qi, Yuxin Xu Department of Ophthalmology, Second Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China Correspondence: Yuxin Xu, Department of Ophthalmology, Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Economic and Technological Development Zone, Hefei, People's Republic of China, Tel +86-13866752297, Email Introduction: TSG-6 plays a wide anti-inflammatory and therapeutic role in a variety of autoimmune diseases as the key mediator of mesenchymal stem cells (MSCs). Purpose: We aimed to test whether TSG-6 could exert similar effects as MSCS in TAO via establishing TAO animal model immunized by hTSHR-A subunit plasmid. Material and Methods: We tested the expression level of TSG-6 on intraconal orbital fat from controls and patients with TAO. We established a stable thyroid-associated ophthalmopathy animal model by immunizing 6-week-old female Balb/c mice with recombination hTSHR-A subunit plasmid. After four immunizations, TSG-6 or dexamethasone was injected through the tail vein. The effects of the drugs on body weight, thyroid function, orbital inflammation, fibrosis and lipogenesis were observed. Results: The expression of TSG-6 in the orbital tissues of TAO patient is lower than that of normal people. In our animal model, mice showed weight loss, higher TT4 and TSHR antibody levels, and ocular symptoms such as inflammation and proptosis. TSG-6 can reduce ocular fibrosis and lipogenesis by inhibiting the infiltration of CD3+ T lymphocytes and macrophages in the mouse model of thyroid associated ophthalmopathy. Compared with dexamethasone, TSG-6 showed comparable anti-inflammatory effect, moreover, it has given a better performance in inhibiting adipogenesis. Conclusion: It was demonstrated that TSG-6 has a considerable positive impact on improving eye symptoms of TAO mice, which could be a novel candidate for the early treatment of TAO. Keywords: TAO, TSG-6, hTSHR-A subunit plasmid, anti-inflammatory, anti-fibrosis, lipogenesis Thyroid associated ophthalmopathy (TAO) is an autoimmune disease caused by the thyrotropin receptor (TSHR) over-expressed, which is disfiguring, vision-threatening and has a substantial negative impact on patients' mental and physical health. The occurrence of TAO is usually accompanied by Graves' disease, also known as Graves orbitopathy. 1,2 TAO is mainly manifested as proptosis, conjunctival edema and upper eyelid retraction. Orbital fibroblasts (OFs) act as both target and effector cells during the pathogenesis, over-expressing TSHR and insulin-like growth factor I receptor (IGF-IR), which synergically lead to T and B lymphocyte infiltration. 3,4 Initially, inflammation, congestion and edema occur in the orbital tissue due to immune responses, which stimulate OFs hyperproliferation and adipogenicity, further lead to overproduction of the extracellular matrix, tissue remodeling and fibrosis. 5,6 In the last decade, researchers have successfully built mature and stable TAO animal modes after many explorations, the mainstream method is to immunize Balb/c mice with recombinant plasmid or adenovirus. 7,8 However, the therapeutic options for TAO are limited and unsatisfactory due to the pathogenesis is not exhaustive, it is necessary to explore novel targets for the treatment of TAO. 9 Tumor necrosis factor α stimulated gene 6(TSG-6) is a well-known anti-inflammatory factor, which plays a positive role in mediating mesenchymal stem cell (MSC) immunoregulatory function and inhibiting the adhesion and migration of inflammatory cells. 10 Previous findings suggest that human OFs display an array of characteristics of MSCs, which play a role in proliferation and differentiation, but in terms of immunosuppression, TAO-OFs perform poorly in reducing T cell infiltration and secretion of inflammatory factors. 11,12 The dysfunction may be closely related to endogenous TSG-6. MSC has been demonstrated as an excellent treatment in TAO. For instance, placenta-derived mesenchymal stem cells (PD-MSCs) inhibit TAO mice orbital fat production through exogenous orbital injection, 13 which decreased a lipid accumulation by downregulating the phosphorylated PI3K/AKT/mTOR expression in OFs from TAO patients. 14 In addition, it was reported that exogenous administration of TSG-6 alone can ameliorate liver fibrosis in male C57BL/6J mice, while TSG-6 knocked MSCs (Lv-TSG-6 MSCs) lost antifibrotic effect, and TSG-6 injection alone was as effective as MSCs transplantation. 15 Hence, we reckon that TSG-6 may have similar functions as PD-MSCs in the treatment of TAO mice model -Abstract Truncated-
immunology